title: Development of a standardized susceptibility test for campylobacter with quality-control ranges for ciprofloxacin, doxycycline, erythromycin, gentamicin, and meropenem.
abstract: A standardized agar dilution susceptibility testing method was developed for Campylobacter that consisted of testing on Mueller-Hinton medium supplemented with 5% defibrinated sheep blood in an atmosphere of 10% CO2, 5% O2, and 85% N2. Campylobacter jejuni ATCC 33560 was identified as a quality-control (QC) strain. Minimal inhibitory concentration (MIC) QC ranges were determined for two incubation time/temperature combinations: 36 degrees C for 48 hr and 42 degrees C for 24 hr. Quality-control ranges were determined for ciprofloxacin, doxycycline, erythromycin, gentamicin, and meropenem. For all antimicrobial agents tested at both temperatures, 95-100% of the QC MIC results fell within recommended QC ranges. Twenty-one Campylobacter clinical isolates, encompassing five species of Campylobacter (C. jejuni, C. coli, C. jejuni, subsp. doylei, C. fetus, and C. lari) were tested in conjunction with the C. jejuni QC strain. While C. jejuni and C. coli could be reliably tested under both test conditions, growth of C. jejuni subsp. doylei, C. fetus, and C. lari isolates was inconsistent when incubated at 42 degrees C. Therefore, it is recommended that these species only be tested at 36 degrees C.
authors.affiliation: Office of Research, Center for Veterinary Medicine, US Food and Drug Administration, Laurel, MD 20708, USA. PMcDermo@cmv.fda.gov
authors.forename: P F
authors.initials: PF
authors.lastname: McDermott
authors.forename: S M
authors.initials: SM
authors.lastname: Bodeis
authors.forename: F M
authors.initials: FM
authors.lastname: Aarestrup
authors.forename: S
authors.initials: S
authors.lastname: Brown
authors.forename: M
authors.initials: M
authors.lastname: Traczewski
authors.forename: P
authors.initials: P
authors.lastname: Fedorka-Cray
authors.forename: M
authors.initials: M
authors.lastname: Wallace
authors.forename: I A
authors.initials: IA
authors.lastname: Critchley
authors.forename: C
authors.initials: C
authors.lastname: Thornsberry
authors.forename: S
authors.initials: S
authors.lastname: Graff
authors.forename: R
authors.initials: R
authors.lastname: Flamm
authors.forename: J
authors.initials: J
authors.lastname: Beyer
authors.forename: D
authors.initials: D
authors.lastname: Shortridge
authors.forename: L J
authors.initials: LJ
authors.lastname: Piddock
authors.forename: V
authors.initials: V
authors.lastname: Ricci
authors.forename: M M
authors.initials: MM
authors.lastname: Johnson
authors.forename: R N
authors.initials: RN
authors.lastname: Jones
authors.forename: B
authors.initials: B
authors.lastname: Reller
authors.forename: S
authors.initials: S
authors.lastname: Mirrett
authors.forename: J
authors.initials: J
authors.lastname: Aldrobi
authors.forename: R
authors.initials: R
authors.lastname: Rennie
authors.forename: C
authors.initials: C
authors.lastname: Brosnikoff
authors.forename: L
authors.initials: L
authors.lastname: Turnbull
authors.forename: G
authors.initials: G
authors.lastname: Stein
authors.forename: S
authors.initials: S
authors.lastname: Schooley
authors.forename: R A
authors.initials: RA
authors.lastname: Hanson
authors.forename: R D
authors.initials: RD
authors.lastname: Walker
mesh_terms: D002167:Campylobacter / Q000187:drug effects* / Q000302:isolation & purification*; D002939:Ciprofloxacin / Q000494:pharmacology*; D004318:Doxycycline / Q000494:pharmacology*; D004917:Erythromycin / Q000494:pharmacology*; D005839:Gentamicins / Q000494:pharmacology*; D006801:Humans; D000077731:Meropenem; D008826:Microbial Sensitivity Tests / Q000592:standards; D011786:Quality Control; D013845:Thienamycins / Q000494:pharmacology*
chemical_list: D005839:Gentamicins; D013845:Thienamycins; D002939:Ciprofloxacin; D004917:Erythromycin; D000077731:Meropenem; D004318:Doxycycline